Skip to main content

Advertisement

Table 1 Treatment initiation and continuation regimens of Phase 3 randomized controlled trial of anti-VEGF in DME

From: Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data

Randomized controlled trial Initiation and continuation regimen Time to maximum mean BCVA*
RIDE/RISE NCT00473382 NCT00473330 Fixed q4 intervals ranibizumab  (no reduction before week 156 in the open-label extension) [4] Week 88/week 92
RESTORE NCT00687804 Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [5, 6] Week 40
RELIGHT NCT01257815 Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [7] Week 24
REVEAL NCT00989989 Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [8] Week 32
DRCR protocol I NCT00445003 Initial 4 q4 intervals ranibizumab followed by protocol-driven ranibizumab retreatment [9] Week 232
DRCR.net protocol T NCT01627249 Aggressive retreatment protocol for IAI, bevacizumab, and ranibizumab prior to 24-week visit with q4 intervals [10] Week 32, week 52
VIVID/VISTA NCT01363440 NCT01331681 Initial 5 q4 intervals IAI followed by 2q8 or 2q4 intervals [11] Week 44
BOLT EUDRACT2007-000847-89 Initial 3 q6 intervals bevacizumab (initially combined with laser) followed by PRN (protocol-driven) bevacizumab retreatment [12] Week 100
  1. q4, every 4 weeks
  2. * Within controlled/core study phase